Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody

Abstract Background Aberrant MET tyrosine kinase signaling is known to cause cancer initiation and progression. While MET inhibitors are in clinical trials against several cancer types, the clinical efficacies are controversial and the molecular mechanisms toward sensitivity remain elusive. Methods...

Full description

Bibliographic Details
Main Authors: Jianqun Kou, Phillip R. Musich, Ben Staal, Liang Kang, Yuan Qin, Zhi Q. Yao, Boheng Zhang, Weizhong Wu, Angela Tam, Alan Huang, Huai-Xiang Hao, George F. Vande Woude, Qian Xie
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Journal of Translational Medicine
Subjects:
Hepatocyte growth factor
Met
Tyrosine kinase inhibitor
Neutralizing antibody
Targeted therapy
Combination therapy
Online Access:http://link.springer.com/article/10.1186/s12967-018-1628-y

Internet

http://link.springer.com/article/10.1186/s12967-018-1628-y

Similar Items